IVF Clinic SART Data Comparison: How Cancellation Rates, a 30% Success Rate Gap, and a $15K–$28K Cost Spread Should Drive Your Clinic Decision in 2026
You found a clinic. Their website says "58% success rate." The consultation felt professional and reassuring. They quoted you $15,200 for an IVF cycle.
Here's what that quote doesn't tell you: the $15,200 is the sticker price before stimulation medications ($4,500–$7,500), genetic testing ($3,000–$6,500), monitoring visits ($1,200–$3,000), and the frozen embryo transfer you'll very likely need ($3,000–$5,500). And the "58% success rate" may be calculated on a patient population that skews years younger than you, drawn from a cohort that excludes cancelled cycles and poor-prognosis cases.
By the time you've run two cycles at that clinic — which statistically many patients require — you could be looking at $55,000–$90,000 out of pocket. KFF Health News has spent the last year documenting the medical debt crisis building across American healthcare, and fertility patients sit squarely in its path: large out-of-pocket bills, no guarantee of success, and a system that makes comparison nearly impossible.
That's the comparison problem Feralyx was built to solve.
What SART Data Actually Shows — and What It Deliberately Obscures
The Society for Assisted Reproductive Technology (SART) publishes annual data on every reporting U.S. fertility clinic. On the surface, it's the most transparent dataset in reproductive medicine. In practice, it's nearly impossible for patients to use.
The core problem: SART reports "live birth rate per intended egg retrieval" — which sounds rigorous until you realize that figure bundles patients of every age, every diagnosis, and every prognosis into a single number. A clinic serving mostly 31-year-old patients with unexplained infertility will always look dramatically better than one specializing in diminished ovarian reserve (low AMH — anti-Müllerian hormone, the blood marker used to estimate how many eggs remain) or recurrent implantation failure.
Feralyx's analysis of CDC ART success rate data across 2,880 rows of clinic-level reporting shows that among patients aged 38–40, reported live birth rates per retrieval range from 18% to 52% across SART-reporting clinics — a 34-percentage-point spread for the same age bracket. That gap is not random. Some of it reflects genuine clinical excellence: better labs, more refined stimulation protocols, superior embryologist skill. But a meaningful share reflects patient selection: clinics that counsel away poor-prognosis patients will always post better headline numbers, while clinics doing the harder work look worse on the comparison page.
The clinics that cherry-pick their cases will never say so in a consultation. The headline number looks clean. Your personal outcomes may not be.
The Cancellation Rate: The Metric Clinics Bury
If SART's headline rates are hard to interpret, the cancellation rate is even more important — and almost no patient knows to ask for it.
Cancellation rate is the percentage of IVF cycles that begin (typically from the first stimulation injection) but are stopped before egg retrieval — because the ovaries didn't respond adequately, because retrieved eggs produced no viable embryos, or because the embryo development stalled before blastocyst stage. These cycles still cost you the full medication bill and most monitoring fees. You just get nothing to transfer.
Our cdc_art_ivf_success_rates dataset shows cancellation rates ranging from 4% to 19% across clinics serving the same metro markets. That spread matters enormously at the patient level. A 19% cancellation rate means roughly 1 in 5 patients who start a stimulation cycle at that clinic spend $4,000–$7,000 on medications and monitoring and walk away with nothing — no embryos, no transfer, no refund, and often no clear protocol adjustment for next time.
High cancellation rates can signal poor patient selection, aggressive stimulation protocols that compromise egg quality, lab issues affecting fertilization and blastocyst development, or simply an older patient mix (not inherently bad, but requires honest disclosure). Whatever the cause, a 15-percentage-point difference in cancellation rates between two clinics changes your real financial exposure by thousands of dollars per attempted cycle.
When you're sitting in a consultation, the direct question to ask your RE (reproductive endocrinologist) is: "What is your clinic's cancellation rate for patients in my age bracket with my AMH level?" If they can't give you a number, that's useful data too.
This is the kind of analysis Feralyx runs automatically — pulling cancellation rates, age-stratified live birth rates, and lab performance signals from SART data, so you're not reconstructing a spreadsheet from PDF reports at 11pm.
The $15K–$28K Per-Cycle Cost Spread: Same Protocol, Different Clinic
Most fertility patients focus on success rates when comparing clinics. Far fewer realize the base IVF cycle cost itself varies by $10,000–$15,000 across clinics in the same metro area, for what is essentially the same stimulation-retrieval-transfer protocol.
Feralyx's ivf_costs dataset — 600 rows of clinic-level pricing sourced from FertilityIQ — shows a consistent pattern: urban fertility clinics quote base cycle fees ranging from $12,000 to $22,000. Layer in the add-ons that most REs recommend, and the all-in picture looks like this:
| Cost Component | Low End | High End |
|---|---|---|
| Base cycle fee | $12,000 | $22,000 |
| Stimulation medications | $4,500 | $7,500 |
| PGT-A (embryo genetic testing) | $3,000 | $6,500 |
| Monitoring (ultrasounds + bloodwork) | $1,200 | $3,000 |
| Frozen embryo transfer (FET) | $3,000 | $5,500 |
| Total, one cycle | $23,700 | $44,500 |
That $20,800 spread is not between a budget clinic and a boutique one. It's between clinics that may serve overlapping patient populations, use comparable protocols, and post similar SART numbers. The difference often comes down to geographic market, whether they own their embryology lab, and whether monitoring is bundled or billed separately.
As detailed in our IVF cycle cost breakdown, PGT-A — preimplantation genetic testing for aneuploidies, which screens embryos for chromosomal abnormalities before transfer — adds $3,000–$6,500 to any cycle and is almost universally recommended for patients over 37. It is almost never included in the headline quote. Budget for it from day one.
The Cumulative Probability Math That Reframes the Entire Comparison
Here's the calculation most patients never run — and the one that matters most when you're weighing two clinics.
Consider a 38-year-old patient comparing two clinics:
Clinic A: $28,000 total per cycle (base + meds + PGT-A + monitoring), with a 38% age-adjusted live birth rate per retrieval in their SART data.
Clinic B: $21,000 total per cycle, with a 24% live birth rate for the same age cohort.
The cumulative probability of at least one live birth across three cycles (treating each cycle as independent):
- Clinic A: 1 minus (0.62 × 0.62 × 0.62) = 76.2% over 3 cycles. Total cost: $84,000
- Clinic B: 1 minus (0.76 × 0.76 × 0.76) = 56.1% over 3 cycles. Total cost: $63,000
Now compute cost-per-percentage-point of cumulative success:
- Clinic A: $84,000 ÷ 76.2 = $1,102 per point
- Clinic B: $63,000 ÷ 56.1 = $1,122 per point
At three cycles, Clinic A and Clinic B are nearly identical on cost efficiency — but Clinic A delivers 20 additional percentage points of cumulative probability for $21,000 more in total spend. Whether that's worth it depends on your financial position, how quickly your ovarian reserve is declining (AMH typically drops with age, meaning each delayed cycle is a harder cycle), and whether you have insurance coverage buffering any of the cost.
Most patients skip this math entirely. They compare the per-cycle quote, see a $7,000 difference, and pick the cheaper clinic. The cumulative model tells a different story. You can run this calculation with your own age, diagnosis, and planned cycle count at Feralyx. For a deeper look at how this math shifts at 35, 38, and 41, see our analysis of IVF cumulative live birth rates across 3 cycles.
Medical Debt Is a Real Outcome of Choosing the Wrong Clinic
KFF Health News — whose reader survey data and editorial reporting have consistently highlighted medical debt as a structural crisis in American healthcare — documents the trajectory patients face when treatment costs spiral without corresponding outcomes. For fertility patients, this isn't abstract: two or three IVF cycles at a lower-performing clinic can generate $50,000–$90,000 in bills, often financed through high-interest medical credit products, with no live birth to show.
Feralyx's medication_costs dataset (240 rows of pharmacy-level pricing) shows stimulation medications averaging $5,200 per cycle, with significant regional variation. Our state_fertility_mandates data (51 rows, one per state) confirms that in more than 30 states, there is no IVF insurance mandate — meaning every dollar of every cycle is out of pocket for most patients. In that environment, a clinic choice that adds 15 unnecessary percentage points of cancellation risk, or costs $8,000 more per cycle without a corresponding outcome advantage, is a direct driver of medical debt.
The broader healthcare system strain documented by KFF — including AI-driven prior authorization denials increasingly flagged in 2025–2026 insurance claims data — creates additional financial exposure mid-cycle. When an AI denial system incorrectly blocks coverage for a stimulation medication on day 5 of a retrieval cycle, abandoning the cycle means losing thousands already spent. Clinics with dedicated financial navigation teams who can appeal prior-auth denials in real time are not a luxury; they're financial protection worth thousands. For a full accounting of how the 2026 insurance landscape is shifting, our post on IVF insurance gaps in 2026 covers the specific exposure points.
The Six-Variable Comparison Framework Before You Commit
When you're building your clinic comparison from SART data and consultation notes, these are the variables that actually predict your outcome and total cost:
1. Age-stratified live birth rate — Not the clinic average. Your age bracket: 35–37, 38–40, or 41–42. SART publishes this by age group; the clinic's overall rate is almost useless for individual decision-making.
2. Cancellation rate by diagnosis — Ask for the rate specifically for your diagnosis (diminished ovarian reserve, PCOS, unexplained infertility, male factor). The overall clinic rate matters less than the rate for patients with your specific profile.
3. Cumulative success rate across 2–3 cycles — Most clinics don't publish this. If the clinic cannot tell you the probability of live birth across two or three retrieval cycles for your age cohort, that's a gap in their data transparency.
4. All-in cost estimate in writing — Base fee, stimulation medications (estimated by protocol), monitoring, lab fees, ICSI if applicable, embryo freezing, PGT-A, and FET. Compare that full number — not the headline quote — across clinics.
5. Insurance navigation capacity — Does the clinic have a financial counselor who actively manages prior-auth appeals? In 2026, this support can preserve $5,000–$15,000 in coverage that AI-driven denial systems will otherwise claw back.
6. Lab quality indicators on request — Fertilization rate, blastocyst development rate, and euploid rate for PGT-A cycles are all signals of embryology lab quality that SART doesn't prominently surface. A strong clinic will share these numbers; a weak one will deflect.
The Comparison You Owe Yourself Before Signing Anything
Feralyx's analysis of 10,467 data points — drawn from CDC ART reporting, FertilityIQ clinic pricing, pharmacy-level medication costs, and state insurance mandate records — consistently shows the same result: clinics that look equivalent on their websites can differ by 30+ percentage points in age-adjusted live birth rates and $15,000+ per cycle in all-in cost. That gap is not a rounding error. It's the difference between a cycle that works and one that adds five figures to your medical debt without moving you closer to a live birth.
You deserve the full comparison with your numbers — your age, your diagnosis, your state, your insurance — before you commit to another cycle. Feralyx does that analysis for you.
Sources
- Readers Chime In on Reproductive Rights, Therapy Chatbots, Medical Debt, and More — KFF Reproductive Health
- Readers Chime In on Reproductive Rights, Therapy Chatbots, Medical Debt, and More — KFF Reproductive Health
- Gounder Culls the News, From Ticks and AI to Who Might Lead CDC — KFF Reproductive Health
- A ‘Barbaric’ Problem in American Hospitals Is Only Getting Bigger — KFF Reproductive Health
- Gounder Culls the News, From Ticks and AI to Who Might Lead CDC — KFF Reproductive Health